error
expect elev premium back
level investor appear price improv
recent data point leav us cautious optimist
model impli modest momentum acceler
sentiment leav littl room flawless
improv feel price discuss extens bp
momentum deceler seen across devic acut
us deceler bp softest perform eight quarter see
economi devic growth problem
analysi could pin weak econom factor unemploy
uninsur etc variou factor could also play flu deduct etc
absenc definit driver challeng strong convict
recoveri said util survey slightli posit
point improv inpati volum acuiti see hospit
survey similar setup turn challeng expect
becom elev follow under-perform april devic
last two month outpac healthcar pt pt
respect coverag trade premium
consist premium model impli bp
momentum acceler vs bp deceler last quarter
manag convers indic broad soft materi
recoveri although tone larg posit throughout bia
result prove stronger us rel given recent
out-performance multipl near histor high expect clearli
assum improv along idiosyncrat guidanc rais see make
ineffici earn difficult find
controversi lie quarter
abiom sentiment remain neg given unexpect
deceler see convinc quarter
usher clear manag suggest trend april improv
dilig suggest full acut recoveri slowdown
like rp driven rather multi-quart slowdown
high risk pci began recent invest new territori
rep may take longer one quarter effect
comfort street estim y/i growth mse
street estim alreadi midpoint
guidanc rang suggest guidanc rais low may
return rel current stock price
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
expect hope sustain remain time
final ipp rate august less like yield type revers
zimmer biomet cc organ growth estim adjust
sell day dynam impli bp momentum improv
admittedli challeng zimmer biomet overcom recent
past said combin cfo transit rosa concern
lower expect quarter cfo transit
link acut chang fundament view see
rosa dilig indic materi issu system see
stock trade discount larg cap peer vs
head earn setup look interest
radic shift market growth certainli cloud
intermedi term outlook said competitor commentari
check intra-quart indic implant pick modestli
combin risk adjust guidanc comfort
deliv midpoint guid expect annual
guidanc set conserv remain comfort
bp street catalyst path encourag backhalf
discuss post suggest enthusiasm
multimod omnia platform launch pdn nsrbp data
thought potenti guidanc revis
organ growth estim impli momentum
stabil see achiev lead potenti guidanc
growth vs guidanc cc despit challeng comp
comfort acceler base neotract rep hire
comp eas dtc market expans intervent growth
sustain hsd ldd growth manta traction build
distributor re-stock tailwind howev fx movement remain
unfavor guidanc less confid
bottom line rais given current rate impli addit headwind
ep despit still see top end ep guidanc
achiev driven revenu upsid favor product mix
restructur program cost initi
model organ growth impli bp
momentum deceler may prove conserv softest
comp year momentum stabil would impli organ growth
organ modest guidanc revis would possibl
howev recal uncharacterist rais organ growth
meet reaffirm confid continu mako traction medsurg
durabl see trend sustain potenti
greater leverag see
abbott comfort organ growth impli
bp momentum acceler model conserv impli
pt deceler diabet bp deceler
cardiolog neuromod model organ growth
impli stabil vs believ manag could rais
low end organ guidanc libr icgm approv key focal
point account drive increment upsid estim
earn comfort could see rais
low end within current guidanc
intuitive/edward perform gap narrow quarter battl
high growth large-cap edward outperform intuit ytd
chang quarter
intuit question system placement mix competit
weigh share last vs
group lag year pt like better number
front system mix improv sp manufactur
recov china tender begin flow procedur number
repres bp deceler see potenti
upsid medtron robot analyst day schedul septemb
remain overhang think stronger result compani
edward growth expect organ growth total
edward tavr repres momentum stabil
reason check suggest materi low-risk inflect
modest q/q improv tavr growth like sustain
enthusiasm improv backhalf post ncd
dilig continu support pascal key area upsid see
tvt dilig run rate impli pascal sale vs mse
total mitral path upsid driven faster
see upsid smid quarter
expect materi upsid estim model pt
momentum deceler unlik materi libr
prove expans shift pharmaci outweigh price
headwind perform post-ada suggest move past libr
risk see still expect volatil near-term start abbott
earn wednesday weak post abbott commentari
libr creat buy opportun quarter
guidanc impli bp momentum deceler
us like repres conservat light channel shift
dash headwind prove manag light broad us
momentum see upsid sale estim
street impli back half outlook may also prove
conserv given current model momentum stabil
remaind year dilig ada construct see
visibl sale increas increas visibl ex us
sale post anniversari ypsome dash convers horizon
updat focal point
irhythm see upsid sale
street estim impli q/q growth
q/q growth seen past two year mid singl digit
percentag beat versu model beat impli bp
momentum deceler line histor trend given
reimburs overhang see irhythm least consensu
amongst three high growth smid clariti juli
whether zio code review ama septemb may
sentiment implic reimburs debat
updat price target number compani reflect chang peer
summari price target chang
exhibit summari price target chang
medic devic coverag under-perform
bp health under-perform coverag pt coverag
outperform provid servic pharma
within coverag cardio suppli show strongest
perform ortho equip rel weaker
med-tech sector
med-tech capit
ntm price-to-earnings rel
ntm price-to-earnings rel
exhibit cardio ntm price-to-earnings rel
exhibit ortho ntm price-to-earnings rel
exhibit suppli ntm price-to-earnings rel
exhibit organ growth med-tech segment
exhibit year stack organ growth med-tech segment
exhibit organ growth capit
exhibit yr stack organ growth capit
exhibit ms med-tech coverag base case return rel
current stock price
return rel current stock price
million except ep
comfort organ growth comfort
organ growth estim line guidanc
street estim organ growth impli bp
momentum acceler driven bp acceler
epd bp acceler dx aler growth improv
model impli pt deceler diabet
seem conserv given pace libr new patient
add note increment diabet sale
bp corpor growth still impli bp ww
diabet momentum deceler model bp
acceler cardio neuromod driven structur heart
see mitraclip remain acut focus
momentum stabl abbott lose share peer
neuromod pt deceler expect slight
recoveri growth expect fx line manag
guidanc headwind remain comfort high
end earn rang
rais low end rang similar prior year
expect manag rais guidanc expect rais
low end rang top bottom line
comfort organ growth estim
upper half current guidanc possibl
manag rais low end rang earn
comfort upper half
rang see path increas low end
libr key focu call diabet model growth us
pt momentum deceler growth ex us impli pt momentum
deceler libr ad patient last quarter instal base grew
patient suggest deceler model conserv
note increment diabet sale bp corpor growth still
impli bp ww diabet momentum deceler given libr
announc ada expect libr continu signific focu
call continu expect approv via icgm pathway abbott broader
data set seen ada expect updat commentari time
manag previous suggest approv expect updat
payer momentum pharmaci continu discuss tier
mitraclip acceler ahead ncd coapt landmark trial mitraclip
fundament chang treatment paradigm secondari function mitral
regurgit fmr patient said near-term challeng
promin tvt includ identifi appropri patient cohort establish
protocol team appropri patient manag drive referr us
mitraclip growth improv momentum
stabl period expect continu remain
comfort y/i growth continu expect ncd approv
backhalf serv catalyst adopt given aforement
challeng comfort global market growth stabil
year inflect estim remain risk-adjust
mitraclip pascal see potenti upsid driven ncd
anniversari mitra-fr disrupt pascal launch ex us see
increas pt rais pt prior base ep
reflect increas larg cap peer multipl valuat methodolog base
premium larg cap peer base peer growth rate multipl
line high growth peer abbott boston
million except ep
street estim achiev unlik
clear result materi weaker expect sale
momentum deceler pt pci patient volum
deceler pt rp concern
dilig suggest broad weak rp driven
util seem deceler earlier year
pci volum deceler pt manag discuss
earli trend april improv acut slowdown
march takeaway ceo meet may suggest
acut improv less like still unclear whether
weak driven commerci disrupt intern
market dynam given issu may evolv
singl quarter expect acut solut singl
quarter commentari suggest manag reinvest
sale forc increas sale rep hire reps/quart
materi given trend closer
reps/quart ad two new region territori look
forward updat commerci traction initi
expect rais low end
guidanc given commentari call suggest
improv think quarter
demonstr acut recoveri all-clear stock
comfort street estim y/i growth mse street
estim alreadi midpoint guidanc
rang suggest guidanc rais low end less interest sustain
growth level investor look
catalyst path weve previous said catalyst path less
robust prior year creat void sustain growth look updat
number smaller item ex us outlook japan may prove
conserv traction reacceler cours year today model
line guidanc stagnat vs updat franc
reimburs possibl see reimburs cp
surgeon may push back launch contribut growth
reimburs unlik get revis posit prior year ipp
propos rate repres rate cut drg account
procedur prior year final rate revis meaning
posit think less like see revis year expect final
rate next year profit driver build continuum
care around impella linear relationship
reimburs utilizaiton econom driver adopt said
level reimburs adequ cut still repres signific
headroom impella procedur ergo less convinc cut lead acut
slowdown util near term though may weigh sentiment investor
question longer term stabil rate correspond implic
million except ep
first full look focu shift profit pt
first time alcon provid full allow
comprehens look financi statement post-spin
receiv top-lin margin commentari alcon
trade updat see solid start note expect focu
shift revenu profit quarter remain
optimist greater ep visibl support premium valuat
discuss initi see alcon deliv upper-teen
ep growth rest large-cap med-tech
justifi higher price-to-earnings multipl updat price target
ep estim discount back year reflect
increas peer multipl sinc initi model
revenu impli organ growth though
pt momentum deceler high point
year predic season strength contact lens
ocular health core oper margin low point
year base step-up oper expens tie
consum advertis categori remain
high-end growth guidanc model cc growth
versu guidanc midpoint core oper
guidanc continu model ep
ep rel in-lin consensu
eye panoptix updat earn call
look updat commentari around key pipelin
product within surgic includ emphasi panoptix
ex-u traction contribut surgic strength
us launch time expect late earli within vision look
commentari around launch time also expect late earli
new manufactur line current undergo optim also
look commentari market share dynam contact lens alcon cede
share segment last quarter due promot price peer particularli
mass sihi segment competitor appear eager lock custom ahead
million except ep
still one quarter away meaning growth acceler
lower pt saw low point avano
growth earn see note model
revenu in-lin consensu impli bp
organ growth follow flat organ growth look
meaning organ growth acceler back half
year order avano reach lower end fy sale
guidanc model organ growth ramp
respect though acceler primarili due
easier comp lower comp driven larg part on-q
headwind acceler impact throughout
addit distributor order/destock time see two
driver could help avano grow lower-end
suppli recoveri on-q acceler coolief
follow clinic direct-to-pati dtp invest
lower price target base ebitda
discount back reflect discount peer due
expect oper margin improv begin
expect oper margin improv throughout year driven lower invest
spend larg relat coolief cost save build throughout year
higher level sale model oper margin quarter
improv respect
given back-half focu unlik debate-alt nonetheless
monitor commentari number key topic includ
on-q recoveri anticip greater visibl manufactur suppli recoveri
quarter
coolief growth manag like remain bullish prospect
coolief given recent direct-to-consum market effort potenti
reimburs chang expect mid juli prior earn
transform larg invest year avano though cost
save expect build throughout year
 acquisit remain key focu manag follow si
divestitur near-term expect deal remain rel small focu
near-adjac potenti larger deal cost transform
plan along
million except ep
r-snm approv greater catalyst believ modest
revenu contribut axon ex us r-snm devic could
drive upsid number real focu stock
remain r-snm approv us see readi await
manag provid earn call around
approv launch time use vein
look updat around salesforc hire axon
remain ahead schedul rep follow
anticip salespeopl time launch upper
end initi rep target rang current model
sale rep us devic approv launch late
though model remain base conserv data-
driven pma process timelin possibl axon receiv
approv sooner perhap even prior earn
continu see case number prove conserv pt
model revenu consensu
importantli model revenu rel con us
contribut first seen discuss conserv model
late approv launch us approv ahead schedul would clearli drive
upsid revenu estim year continu see case
estim prove conserv fda approv come next week month
path commerci de-risk updat price target
base ev/ sale reflect multipl increas line peer
remov discount back previou target
million except ep
look upper end pt baxter guid organ
growth ex-cyclo impli pt momentum
acceler midpoint model organ growth
consist midpoint guidanc in-lin
street though expect baxter deliv upper end
guidanc base softer comp us nutrit combin
shift tender order ex us ii improv deliveri
model pt momentum acceler iii
continu contribut recent pharma launch follow
quarter expect continu momentum acceler
throughout remaind year pt
new product launch contribut growth slightli easier
comp deliveri drive organ growth
segment pt overal growth updat price
target repres base case ebitda
estim reflect increas peer multipl
margin guidanc attain model oper margin
inflect higher back half drive oper
margin midpoint remind margin expans impli
bp expans includ bp headwind brevi cyclo fx
impli bp underli improv remain comfort
headwind driven brevi cyclo revenu degrad potenti off-set
gener busi leverag upsid higher-margin segment
execut deliveri remain key stabil long-term
valu driver thesi corpor growth lrp deliveri remain
primari focu item investor overhang lighter deliveri
perform key focu see though manag maintain
segment guidanc absolut dollar basi critic year
model impli q/q increas vs averag
sever factor leav us comfort achiev extra sell day vs ii
new oem contract iii recaptur initi baxter deliv focu
shift back-half acceler note bar remain elev
baxter need continu execut meet meaning momentum step-up
impli segment growth guidanc
million except ep
growth high-end get bd low-end
paclitaxel question subsid follow june
adcom view clear event bd least
near-term see fda panel conclud mortal signal exist
ptx path forward continu expect
reduct dcb revenu line
compani seen date compani guidanc
follow view statu quo focu broaden
remaind year look
momentum acceler pt pt
corpor level stem improv across
busi see organ growth term model
quarter translat total revenu roughli in-lin
consensu necessari rang
compani reach growth year lower end
origin guidanc note manag indic
still comfort low-end rang
back-half acceler broad-bas pt rise
follow underli growth underli
growth need upper end rang reach
growth year discuss note see
repres pt sequenti improv back
half driven move past flu bp md
distributor inventori dynam bp bp
underli acceler driven combin peripher
product venovo covera tva surgeri progel move
strong growth higher revenu synergi pertain margin guidanc
impli pt lift higher histor point lift evenli driven
gross margin includ pt smaller fx headwind sg leverag
revenu acceler year top-line underli growth estim remain
low end rang though ep estim fall midpoint
guidanc see greater clariti margin improv revenu
updat price target base case ebitda reflect
increas peer multipl
million except ep
comfort top half guidanc model organ
growth bp momentum acceler bottom half
guidanc rang line acceler
easi receiv question
manag reiter guidanc analyst day
said expect manag reiter guidanc
high convict boston deliv acceler
laid bridg growth see
comfort top half guidanc rang model
reflect bp momentum acceler cardiolog
driven sentinel turn organ lotu launch bp
acceler rm bp acceler medsurg
comfort guidanc sustain growth longer
term expect manag chang
organ guidanc remain comfort
estim midpoint estim impli bp
acceler backhalf continu convict
boston deliv detail see bridg
acceler analyst day boston laid new lrp
larg line preview assumpt includ organ growth
vs mse wamgr vs mse bp margin expans line
mse doubl digit ep growth vs low mid-teen mse guidanc
encourag demonstr sustain best class outlook amongst large-
cap devic peer sustain tripl threat thesi
btg next major catalyst analyst day enthusiasm btg asset
clear support construct view deal boston recent divest certain
bead asset satisfi regul expect deal close august remain
comfort year year without
pharma divestitur see boston may opt reinvest accret
increas pt rais pt prior base
ep reflect increas larg cap peer multipl valuat methodolog
base premium larg cap peer base sustain high singl digit organ
growth profil multipl line high growth peer abbott
edward
model momentum deceler stabil impli
anoth beat updat guidanc
revenu impli y/i growth model
sale come slightli consensu
impli y/i growth contribut
total fy revenu us model y/i growth ex
us model y/i growth though model pt
momentum deceler quarter expect prove
conserv given continu robust new patient add
recent track record revenu beat compani
deliv beat vs estim past consecut
quarter momentum stabil impli top-lin beat
would expect rais least line beat also look
updat manag guidanc impact
revenu us price pharmaci shift
competit account current guidanc model
volum offset price
libr icgm still like despit fail receiv approv
ada june dilig suggest abbott broader data
present confer expect
signific focu abbott call view libr still like
receiv approv icgm design year ada
note though approv launch like impact sentiment would
expect minim impact new patient add given continu
expand penetr
ada commentari keep us confid long-term manag commentari
ada gave us increas confid sustain growth profil
reinforc view lrp guidanc sale may prove
conserv continu pursu premium price strategi given
premium offer analysi elast suggest price concess would drive
volum compani flexibl libr price becom bigger driver
payor formulari prefer shift shift pharmaci manag
highlight coverag increas next year total us
volum ex-medicar possibl shift channel drive meaning
oper leverag discuss earn note improv
function fulli dispos offer importantli offer cost
improv push type market libr current see
traction given lower price point
million except ep
expect seem reason enthusiasm low-risk
inflect backhalf emerg pascal sale key focal
point model sale slightli street
vs guidanc estim
impli organ growth momentum stabil
impli q/q growth line q/q
growth prior two year investor
expect low-risk inflect tavr growth miss
expect number quarter import
edward deliv q/q improv line estim
mitral second key focal point pascal drive upsid
current mitral guidanc discuss given
earlier expect approv critic growth impli
bp deceler surgic sale impli
stabil manag commentari point growth improv
cours year model reflect growth
improv bp total edward vs low-
risk mitral key driver room upsid
discuss
comfort midpoint tavr guidanc first quarter result
confirm deliber slower roll ultra centera rational
delay becom clear highlight tvt see slower ultra
delay centera derail path mid-point tavr
guidanc edward signific enthusiasm low-risk fda approv
dilig broadli support overwhelm shift tavr clinician
definit low risk inflect rel intermedi evid
increment market movement prior approv ncd said slower valv
rollout put greater onu low risk inflect backhalf expect modest
benefit low-risk remain comfort midpoint rang
mitral upcom catalyst edward guid mitral sale
could prove conserv given earlier expect ce mark pascal see
pascal deliv sale half quarter contribut suggest
deliv assum acceler util overli
conserv dilig tvt construct pascal adopt given edward
strong presenc amongst intervent cardiologist broad similar mitraclip
possibl edward deliv mitral sale vs mse driven
faster roll-out pascal mitral deliv upsid scenario edward could increas
guidanc note increment mitral bp benefit thv
growth bigger focu outlook share dynam vs abbott
discuss post-tvt see
increas pt rais pt prior base
ep reflect increas larg cap peer multipl valuat methodolog
base premium larg cap peer base peer growth outlook
emerg opportun multi-billion dollar market mitral
million except ep
busi key driver strength recent quarter
robot number move lower expect trend
continu despit biolog headwind anniversari
model impli pt momentum deceler core
spine may prove conserv us ex biolog
model organ growth pt momentum deceler
howev assum similar biolog impact model
impli momentum stabil growth
slightli aid distributor order howev easiest
comp year expect upsid expect
globu disclos trauma contribut howev manag
express comfort consensu model
revenu model low end expect
revenu trauma build throughout year
look commentari sale forc ramp
robot season real competit pressur
discuss excelsiusgp placement clear focu area investor
becam even debat follow weaker expect placement
vs mse weak driven varieti factor includ
season pent-up demand creat challeng comp
competit system creat longer sell cycl aggress market tactic
competitor latter two relat structur competit pressur
overli concern investor given robot ramp earli cycl caus
consensu estim fall model robot placement vs
consensu remain cautiou commentari
sound much posit robot ramp see
margin like pressur oper margin materi weaker
estim declin pt y/i although includ sever one-tim
headwind incl fx litig result bp drag margin
notwithstand headwind margin would still declin bp y/i
due elong sell cycl robot well increas
invest see model oper margin bp y/i
improv expect upsid given commentari suggest
reinvest like remain eas moreso
million except ep
expect high steep acceler impli pt
follow strong guidanc help
de-risk lrp see outperform
coverag pt investor expect move higher
quarter revenu estim slightli
consensu howev impli pt organ
momentum acceler mainli driven blood center pt
momentum accel hospit pt momentum accel
discuss despit remain
comfort compani abil deliv guidanc
howev note quarterli cadenc may vari ep model
street also comfort
given compani track record deliv consensu
ep updat price target
ebitda estim reflect increas peer multipl
comfort plasma hospit blood center segment
impli meaning acceler discuss
plasma organ growth estim impli pt momentum acceler
remain comfort note blood center hospit segment impli
steeper acceler pt respect remain cautiou
given compani track record spotti segment compar
frame context lrp plasma guidanc emb north
america plasma market growth low-teen vs includ current
sign contract track meet lrp target
plasma revenu current sign contract faster market growth alon larg
custom contract would provid upsid number regardless manag
posit structur outlook busi blood center hospit
look track behind lrp goal though note anniversari contract
exit next year teg trauma indic help respect regard
profit manag indic haemonet meet ebit lrp
target without new plasma contract remain construct ep growth
derisk stori limit downsid risk investor think
close later year
million except ep
good sold
growth high-end includ voalt top-line
estim line consensu reflect
core growth impli pt momentum acceler
high-end guidanc first quarter hill-rom
incorpor voalt core organ growth account
compani guidanc model follow
beat rais discuss core growth guidanc
impli core growth momentum stabil
look achiev hill-rom narrow ep
guidanc last quarter top end rang
vs prior remain comfort high
end guidanc model subject close time
recent asset divestitur
look updat commentari around pipelin em
growth call manag indic pipelin
product contribut ytd revenu
posit compani well meet target
new product hill-rom continu transform
faster grow market divest lower-growth asset
evidenc recent recent sale surgic
consum discuss revenu
come growth market centrella growth
contribut may decreas later year challeng comp broader
pipelin spotvis retinavu integr tabl motion voalt help bridg
gap look commentari end call hill-rom
indic plan grow invest emerg market initi half
expect see benefit toward end em account hill-rom
revenu today interest detail manag provid term
em invest spend expect growth contribut
million except ep
expect perform top end rang pt
deliv cc revenu growth
quarterli guidanc rang quarter easiest
comp year anticip similar outcom
manag deliv cc revenu growth top end
cc growth rang reflect pt comp-
adjust deceler although convers rang impli
flattish momentum ex cynosur expect diagnost
remain stabl molecular continu
drive dd growth breast stabil brevera recoveri
contribut breast busi growth updat price
target ebitda estim reflect
increas peer multipl
sustain breast dx segment focu strong
perform breast posit backlog trend led
elev expect met breast
momentum deceler pt major slowdown attribut
slowdown gantri like flattish vs perform ii brevera
suppli constraint may cost growth contribut year
bp breast model impli pt momentum acceler breast
challeng comp diagnost proven stabl growth driver
molecular intern drive part guidanc rais throughout year
expect momentum stabil dx model organ potenti
upsid come recent array approv also expect investor focu
commentari regard dx divis head departur public compani ceo job
intra-quart potenti implic busi
path forward cynosur follow growth sentiment
low manag discuss sale forc stabil increas competit
pressur fda regul mlt vitalia primari sourc recent
weak look potenti in-licens opportun add product
bag attempt return growth although manag anticip
cynosur grow model growth growth taken
tabl would taken posit investor
upsid sale estim pt model sale
y/i growth vs guidanc
street see upsid high end
guidanc better detail us model
vs street impli bp
momentum deceler repres conservat light
channel shift dash headwind prove manag
light broad us momentum expect commentari
pharmacy/dash transit includ updat cover
live manag end cover live
expect full coverag month ex us model
vs street expect increas clariti
underli ex us growth guidanc growth post-
ypsome muddl channel destock look
return high-teen underli growth becom
clear increas visibl ex us sale post anniversari
ypsome dash convers horizon updat focal
point rais price target base ev/
sale mark market increas peer multipl
valu line peer vs discount prior
visibl sale increas driven us acceler
increas visibl organ growth ex us ypsome
updat path discuss follow ada see
visibl path increas remain confid
manag abil meet target receiv clariti confer
around market expans natur share captur opportun embed pay
go pharmaci model impli us growth
possibl us growth acceler level increas
visibl sale driven increas access pharmaci ii tam
expans via medicar medicaid iii increas econom shift
dash increas annual exist patient revenu remain
construct abil deliv lrp guidanc gm mid-teen
om see upsid estim acton facil come on-line
volum shift away dme pharmaci
million except ep
dynam favor like better
number front asps/system mix improv sp
manufactur recov china tender begin flow
procedur number line repres
bp deceler adjust sell day see
potenti upsid driver acceler could includ
ex-u expans china japan india taiwan sp earli
launch cycl bariatr surgeri
stapler help drive penetr see sage
recap broadli believ deliv stronger result
though appreci competit overhang
last septemb
comfort street system placement estim
model gross system placement quarter
consensu system placement estim reflect
y/i gross system placement growth vs y/i averag
growth rate last quarter multipl factor includ
potenti procedur upsid leav us comfort
upsid system placement vs street estim
comfort intuit deliv system placement
street estim recent quarter driver system placement
includ uptick oper leas model oper leas mix vs
year ago da vinci also interest sp traction
manufactur recov china tender begin flow quarter
model system placement respect
quarter provid updat pipelin catalyst still remain
strongest pipelin year decad key item includ ex-u expans sp ion
stapler augment realiti expect hear updat sp roll-out
plan ion launch model modest revenu contribut start
progress key market procedur us bariatr china new
quota japan
million except ep
posit quarter reaffirm commerci traction
model sale street
estim impli q/q growth q/q growth seen
past two year mid singl digit percentag
beat versu model beat impli bp
momentum deceler line histor trend
note model impli q/q rev/rep growth account
new rep hire beat impli q/q rev/rep
growth expect posit quarter reaffirm
commerci traction continu increas confid
competit risk overplay would expect
manag rais guidanc beat model
street line high
end revenu guidanc rang
confid continu build backhalf irhythm
broad coverag roll-out devic
financi driver
reimburs remain key focu short report earlier
year focus potenti reimburs pressur pend
shift perman code driven under-perform
manag laid strong fact-bas stanc
reimburs call see overhang
remain next updat process juli
ama releas agenda septemb meet zio code list
septemb agenda expect process begin next meet date may
regardless expect code chang prior
demonstr leverag focu remain near-term reinvest profit
path ebitda break-even key focu investor oper
leverag encourag give investor comfort path
profit gm improv anoth bp oper leverag
meaning remain comfort opex estim
sale focu near term continu growth profit given multipl
data point suggest model work notabl matur rep product
increas rev/rep averag peak year ago well
rev/rep seen broadli med-tech see
million except ep
organ growth bp momentum deceler
challeng comp year bp consensu
reflect slight increas pharma estim discuss
base april/jun im data suggest slightli line
modest upsid achiev believ consensu
model conserv segment note momentum
stabl would impli organ growth pt
guidanc suggest bp guidanc rais may order
would consist rais cc growth
guidanc earn call model impli
organ growth slightli top end
guidanc remain comfort ep estim
consensu mainli driven incom
assumpt mainli outsiz gain asp divestitur vs
consensu discuss like high
 watermark year estim indic
annual ep come vs last year
pharma number look line analysi april/may
im data leav us view pharma number look
slightli line prior quarter modest upsid
possibl adjust estim modestli higher remicad impli
momentum stabil still model y/i headwind biosimilar
stelara intra-quart commentari indic expans posit zytiga
base im trend suggest estim like overli conserv
estim move modestli lower prezista/prezcobix imbruvica reflect
im trend model organ growth pharma
still reflect previous discuss headwind see
look vocal year guidanc look conserv
outsiz exposur pharma face structur headwind talc litig
balanc risk-reward move past key talc litig item fall
multidistrict litig new jersey affect outstand case like
begin hear july/august investor focu pharma stori
acceler above-market growth look like invest case becom
attract driver year includ execut expect
balanc growth profil remov talc opioid litig overhang
million except ep
guidanc reason set guid sale
high confid deliv quarter
new manag like set highli risk-adjust outlook
comfort midpoint slightli
street estim impli pt momentum
deceler nearli pt deceler
market unexpectedli slow commentari boston analyst
day suggest modest improv market
channel check reinforc physician seen
improv volum model impli q/q growth
q/q growth prior
two year note reflect declin us revenu
exclud inventori dynam could
base trend reflect closer declin
underli basi see
outlook focu estim sale vs
impli respect expect
issu guidanc call
comfort estim bp street
model impli pt momentum deceler vs
q/q sale growth q/q growth
q/q averag increas
respect prior three year
market growth share result go definit market
growth unfold next month think give
market growth estim go forward market growth need return
intermedi term focus rel chang
look share stabil near term compani move past
disrupt commerci organ given market volatil quarterli share
dynam less focu ahead share gain omnia
catalyst backhalf intermedi term market growth
speed effect commerci initi improv growth focal
point new platform launch clinic outcom key trial also key
proof point stock check suggest interest multi-mod
omnia platform launch meaning driver growth
expect see senza-pdn data possibl nan ada
senza-nsrbp data sometim later said stock alreadi seem
price manag abil transform compani expect
seem suppress
increas pt rais pt prior base
sale still repres meaning discount high growth smid-cap comp
group trade sale question market growth
million except ep
acceler model howev lesser extent
model organ growth impli pt
momentum acceler follow upsid despit
deliv pt momentum acceler see
help de-risk steep acceler bake guidanc
model impli momentum acceler
pt suggest guidanc yet fulli bake
visibl achiev annual guidanc
import investor regain comfort stock
achiev guidanc despit result
easiest comp year deliv pt
less acceler need back half year comp
becom challeng prior street impli
pt momentum acceler vs reach mid-
point guidanc pt need nuvas
deliv pt momentum acceler impli
model see annual guidanc achiev acceler
driver includ improv within biolog start
recogn revenu puls adopt
margin upsid invest away although manag back away
bp annual margin expans target margin strong
gate bp y/i howev guidanc bp expans adjust
manag discuss plan invest scale throughout year puls
robot boundari model eu mdr steril packag expect addit clariti
cadenc invest spend margin expans model margin
bp declin may prove conserv
analyst day nass key catalyst watch plan host
investor day august expect new ceo outlin compani short
long-term strategi margin opportun robot like nass strateg
prioriti nuvas plan unveil robot prototyp nass septemb
anticip mani detail disclos earn call howev
manag discuss integr puls combin
intern extern develop expect initi launch match
offer globu although manag confid offer
compar believ offer help fill gap
million except ep
estim seem conserv model sale
line street sale repres
q/q sale growth rel q/q growth
improv q/q growth
increment sale impli upsid vs current
estim seem achiev
momentum evid earli year call shockwav
guid sale prior
estim high end beat
commerci roll-out acceler expect similar dynam
guidanc rais least beat q/q
sale continu impli upsid rel
estim line
continu commerci traction work derisk sale
estim repres y/i growth
catalyst horizon near term stori driven
commerci execut manag drive util current
center roll cathet new center cathet
btk next key catalyst limit releas acceler
cours year broadli launch along
two smaller cathet suit smaller btk vessel
atk partnership continu drive
util larg bore procedur coronari data late earli
driver util interim eas use safety/efficaci profil
drive adopt continu enrol timelin data remain
unchang remain unclear impact paclitaxel mortal signal dcb
ivl util may modest driver expect
definit clariti whether trail restart expect manag remain
optimist given patient profil higher risk fda panel recommend dcb
remain market
million except ep
similar expect signific quarter either
direct revenu growth y/i larg line
estim come surpris given
discuss acceler busi inflect stori
see revenu growth estim impli pt
absolut acceler q/q toughest comp
year upsid estim like de-risk guidanc
expect variou updat reimburs sale forc hire
data public time si-bon earn
august releas propos physician fee
schedul rais physician payment rate code
higher like upsid catalyst share
may drive addit physician interest perform
procedur discuss initi coverag
hire plan rep clinic support specialist
unchang track slightli ahead
manag expect look updat thought
hire plan manag earn call relat
surgeon train convers suggest program
well attend activ thu manag estim
ad addit activ surgeon may prove conserv final si-
bone announc submiss ifus data public toward end
discuss public key catalyst larger payor
coverag polici updat time public provid investor better
understand larger payor review polici potenti
model absolut growth acceler build throughout year discuss
expect materi quarter either direct howev given
sale forc hire begin contribut albeit surgeon
train program progress well addit reimburs decis
come model pt acceler growth rate despit
toughest comp year build throughout year growth
acceler remain comfort model top end manag
guidanc predic acceler driven commerci expans execut
million except ep
momentum stabil like warrant guidanc rais pt
organ growth estim impli bp
momentum deceler vs given easiest comp
year intra-quart commentari
posit mako medsurg particularli estim
impli organ growth growth would
like warrant guidanc rais given outperform
coverag slightli pt june see investor larg
price outcom note manag rais guidanc
bp low end follow organ growth
could see anoth bp top end growth
hold updat price target
ep estim reflect increas peer multipl
medsurg mako commentari construct
toughest comp year endoscopi
deliv pt momentum acceler
camera factor model impli pt momentum
deceler endoscopi like conserv given
camera fulli launch expect
contribut build throughout year model organ
growth medsurg howev note segment key upsid driver dd
growth drive anoth bp total growth ortho discuss
zimmer biomet limit launch rosa tka earlier year like
competit impact mako given earli limit launch initi rosa
placement center zimmer biomet account expect continu momentum
mako given util trend remain strong y/i recent quarter
backlog commentari posit manag convers suggest knee
penetr reach addit detail
integr challeng like show manag acknowledg
integr challeng alreadi seen thu far howev
expect bulk cross-train sell set occur
expect integr issu aris toughest spine comp
year cautiou perform expect improv
model flat organ pf growth manag reiter expect pf growth
spine howev cadenc like shift back half load vs
expect gradual improv throughout year
expect similar underli margin expans stryker margin
bp y/i improv includ bp absorb headwind acquisit
impli bp underli margin expans model oper margin
bp y/i improv howev base signific integr activ
occur slightli cautiou margin quarter howev
margin come weaker due increas acquisit dilut believ
abl off-set gener cost leverag share servic
opportun erp system ration along non-oper altern
tax upsid notabl ep estim line street
remain comfort
million except ep
see number beatabl pt deliv
rare pt momentum acceler challeng
devic backdrop coverag demonstr broad base
deceler quarter see model impli
momentum stabil see beatabl base
neotract upsid intervent estim impli
signific deceler may prove conserv
deliv cc growth would reach organ
could lead guidanc rais updat
price target ep estim reflect
increas peer multipl peer organ
growth margin opportun
neotract upsid like drive guidanc revis
discuss manag neotract guidanc y/i
conserv base neotract deliv growth
ahead expect rep hire begin
contribut dtc market campaign
gener result plan broader roll-out
neotract anniversari suppli disrupt second half
eas compar note manag rais neotract
guidanc could still prove conserv would impli bp
overal growth warrant bp guidanc rais cc
remaind busi demonstr stabil
pipelin catalyst watch tvt convers suggest manta
limit commerci releas track full launch late earli
updat asp trend monitor understand trend
rang remain fluid see manta momentum build
throughout year drive bp organ growth statu
repla bla file watch given slip earlier year
percuv enter full market releas convers thu far
suggest posit surgeon feedback see see pipelin product
contribut may contribut pt growth lrp
discuss great detail see
fx risk guidanc ep guidanc y/i includ
headwind fx major occur howev
guidanc assum full year euro rate would result
benefit ep fx rate hover major
quarter manag alreadi anticip headwind dont see
fx materi risk quarter howev rate stay region
remaind anticip addit headwind ep
rais top-line guidanc see ep guidanc remain constant due
pend risk fx
million except ep
comfort estim model net sale
line street estim impli q/q
sale growth q/q growth seen us
lung sale drive major q/q growth oc
lung roll-out continu standard criteria organ recent
approv label expans extend criteria lung
late driver discuss oc heart cap began
march drive util model limit chang
sale vs us may
declin us oc liver sale given devic still
clinic trial said pace enrol improv q/q
q/q declin model may materi suggest
upsid estim
comfort current guidanc call manag gave
guidanc bracket mse
respect expect center add
consist model today ramp year-
end continu remain comfort model
estim current guidanc expect revenu pick
ratabl cours year driven continu
adopt oc lung standard expand criteria
organ oc lung recent receiv pma expand criteria organ see
manag commentari suggest center may becom activ
could see uptak third quarter model assum lung step
contribut sale remaind ii oc heart cap
continu access program began march broad center initi program
increas shipment drive growth go forward model assum heart
deliv total sale remaind iii model assum liver
sale step pace enrol liver protect may
sustain level enrol stay level point
quarterli increas net sale
robust catalyst path go forward transmed robust catalyst path
includ interim analysi oc liver protect data re-pow trial
superior ii heart expand data iii fda heart panel note
continu model limit liver contribut pend data protect trial
heart estim remain risk-adjust pend oc heart commentari fda
panel approv standard expand criteria organ expect
pleas see initi deep dive market size driver growth full
million except ep
quarter expect break new ground follow
placement model impli system place
placement revenu expect backlog improv
increas reflect
addit gross order compani us
oper fulli place expect manag address
view new radiat oncolog model could
posit implic technolog platform
commentari backlog address market
monitor commentari note sever system
placement non-academ center noteabl
initi view near-term address market would
focu mainli academ center given higher price point
mr linac backlog commentari result also strong
order order less seen
would normal season light quarter capit
equip commerci team larg place
target potenti custom lead us believ
order momentum continu model order worth
gross margin improv focu gross margin
priorit manag current believ take step improv gross
margin resurfac later manag see signific
opportun drive system gross margin seen adjust
upgrad cost peer level go long way help limit futur cash burn
work capit expect tailwind headwind
long-term backlog build adopt occur model free cash flow use
moder margin progress
million except ep
expect come quarter rosa chatter
along recent announc cfo transit rais
anxieti model stabl cc growth line
consensu impli pt momentum acceler
organ adj sell day repres bp
momentum acceler comp becom challeng
see organ sell day adjust momentum
improv import de-risk guidanc
remain comfort estim
cfo transit rais investor concern quarter
recent announc cfo transit see spark
investor concern given close proxim quarter end
guidanc reiter see concern
warrant given understand search conduct
long period time around
transit process convers suggest guidanc
adjust warrant zimmer biomet would
announc concurr
rosa commentari close track although manag
state plan provid quarterli system placement commentari
surround limit launch progress sale strategi surgeon feedback
close monitor given recent technic concern albeit minor rais
impact like remain minim given limit launch focus zimmer biomet
loyalist expect placement mix clinic vs commerci
placement unclear initi quarter launch discuss rosa
revenu driver base case model system
drive bp ww knee organ growth bp total zimmer biomet organ
growth next year although expect meaning quantit guidanc
expect commentari frame expect system placement
taken posit mako vs rosa updat channel dynam addit detail
momentum acceler need deliv begin manag
commentari point growth set forth goal begin
model assum midpoint estim organ growth bp
momentum acceler rosa contribut bp growth base case
scenario impli core busi need acceler bp momentum
basi achiev midpoint manag target see momentum
improv de-risk number
price target base multipl base case
ep line high growth larg cap peer see
multipl reflect abbott better peer top bottom line growth nutrit
recov china imf headwind fade aler stabil gradual return market
growth new product libr confirm mri launch mitraclip
inflect sustain organ growth profil medium term management execut
deal synergi margin grow per year support ep
base case valuat use price-to-earnings valuat larg cap peer
believ justifi given better top bottom line growth line high
growth peer
valu driver includ continu oper margin expans core abbott
combin cost synergi execut st jude aler organ growth
acceler driven devic product launch diabet ep structur heart
risk price target includ emerg market macro slowdown fx headwind
strengthen us dollar failur deliv synergi target and/or growth
acceler aler failur libr mitraclip drive top-line growth
price target reflect multipl base case
sale multipl high growth devic peer support dcf
valuat assum wacc termin growth assum sale grow
driven continu impella penetr protect pci shock
impella growth remain medium term market expans initi
take time develop growth continu inflect stemi repres
meaning expans opportun posit feasibl data rapidli scale
busi reach ebit margin multipl remain high
growth peer lack competit under-penetrated market support
impella revenu growth compound-annual-growth-rate
risk pt includ failur demonstr sustain impella growth
call growth sustain question ii emerg competit ahead
expect market growth present attract opportun new entrant
pressur share price iii reimburs risk annual drg reimburs
variabl
price target alc repres base case ep estim
high end larg cap med-tech given alcon upper tier return profil discount back
year impli ep estim
risk price target includ panoptix gain lower expect
traction ii competit particularli contact lens lower cost on-line
provid iii margin expans take longer materi iv recent manag
price target base ebitda discount back reflect
discount peer due avano lower organ growth profil partial off-set
signific margin expans opportun use ebitda normal
cost transform plan follow ip unit sale
risk price target includ top-line revenu grow upper singl digit ii
signific near-term recoveri on-q pain pump iii avano execut larg
accret iv smid-cap consolid
price target base sale take share grow snm
market model axon launch late rapidli reach upper-teen
market share within year differenti product featur drive share captur
innov acceler snm market growth mid-teen
risk price target includ axon r-snm product fda approv ii
current physician relationship could sticki imagin make difficult
gain share iii next-gener competit respons eventu slow share
gain iii market appetit high-growth pre-profit compani iv high
could deterior impact multipl regardless fundament
price target reflect multipl base case ebitda
in-lin peer given lower wamgr off-set margin expans opportun
assum organ growth margin reach
risk includ medic deliveri nutrit recov expect ii
potenti activ below-wacc return iii inabl gener oper
leverag iv baxter struggl grow wamgr
price target base multipl base case
ebitda rel in-lin peer organ growth improv becom
evid cours new product ramp cost program gain traction
bard synergi integr track bd/bard deal model drive mid-
risk price target includ integr fall behind schedul promis
synergi fail materi ii macro trend get wors competit pressur em
mount iii new product launch fail live expect
price target base multipl base base case
ep assum trade larg cap peer justifi boston superior
emerg growth margin expans opportun leverag profil line
high growth peer ew sustain execut support
acceler high singl digit large-cap growth stori recent build pipelin
program drive sale compound-annual-growth-rate oper margin remain
track bp annual improv next sever year drive mid-teen
risk price target includ unfavor legal develop increas competit
core de market competit product launch failur execut
plan pipelin program integr
price target reflect ev sale multipl base
case sale support dcf valuat assum wacc termin
risk price target includ guardian libr competit greater
expect limit new patient start materi increas attrit ii dexcom
traction medicar limit coverag guardian libr come sooner
expect iii libr forc signific price pressur limit path
profit delay failur pipelin catalyst
price target base base case earn
peer justifi above-p growth outlook support discount
cash flow model assum wacc termin growth
model project tavr market growth billion drive ebit margin
incorpor valu reflect mitral option
risk price target includ acceler competit
us near term robust commerci traction boston abbott/st jude
long term ii potenti pipelin develop failur mitral space
market opportun could larger aortic least sever year away iii
reimburs structur us europ could put downward pressur price
time
price target deriv sum part analysi support
ev/ebitda multipl impli core busi ebitda valu
globu robot program trauma launch
risk price target includ increas turnov among sale forc
lower iv robot uptak limit
price target reflect ev/ebitda estim premium
upsid risk price target includ higher price benefit nexsi ii
identif addit cost opportun iii capit deploy downsid
risk includ nexsi disappoint ii cost save fail materi iii blood
bank slow materi iv teg disappoint
price target reflect ev/ebitda multipl discount
smid cap med-tech given leverag lower growth pipelin product move hill-rom
structur organ growth rate mid-singl digit time compani execut
lrp emerg market begin inflect improv stabil growth visibl
margin improv drive multipl higher
risk price target includ pipelin traction slow fail materi
upcom product ii intern sale disappoint iii margin leverag prove
difficult iv materi shift capital-expenditure environ
price target base multipl base case
ebitda discount larg cap devic peer market
satur increas regul limit cynosur growth segment grow
expect growth rate increas competit surgic lead novasur
declin breast health grow lsd-msd new product launch recent drive
growth diagnost price risk manag off-set panther placement
util deliv organ sale growth high singl digit ep growth
risk price target includ deploy capit enter faster growth end
market drive ep growth greater expect share buyback
synergi ii ccynosur recov faster anticip abl achiev doubl
digit growth profil iii novasur manag competit threat
price target reflect ev sale multipl in-lin
high growth smid cap peer ex us growth improv meaning ypsome
gross up us growth remain stabl driven medicar
shift pharmaci mdi pediatr posit insul omnipod ap
competitor risk remain path sale clear like
floor pipelin product sustain growth horizon ap launch
downsid risk includ insulet lose market share ap competitor ii limit
convers anima patient iii ypsome disrupt greater expect iv
horizon ap timelin slip path profit becom less clear upsid risk
includ minim disrupt ypsome transit ii disclosur addit
